

Table S4 Parameters used in the cimetidine PBPK model

Parameter (unit)	Value	Reference
Physicochemical		
pKa	6.9	1
logP	0.48	1
Absorption-related		
k_a (/h)	0.70	1
T_{lag} (h)	0.15	1
FaFg	0.92	1
Distribution-related		
$f_{u,cim}$	0.80	1
R_b	0.97	1
$K_{p,adipose}$	0.24	1
$K_{p,muscle}$	0.86	1
$K_{p,skin}$	0.72	1
Liver-related		
PS_{act} (L/h)	12.0	2
R_{dif}	1.16	2
CL_{met} (L/h)	11.3	1
Kidney-related		
P_d (m/h)	7.9×10^{-5}	3
λ	0.1	4
$K_{m,OCT2}$ (μM)	72.6	1
$V_{max,OCT2}$ ($\mu mol/h$)*	7265	1
$R_{OCT2,inf/eff}$	1.32	5
$K_{m,OAT3}$ (μM)	161	1
$V_{max,OAT3}$ ($\mu mol/h$)*	4124	1
$K_{m,MATE}$ (μM)	7.7	1
$V_{max,MATE}$ ($\mu mol/h$)*	453	1

k_a , absorption rate constant; T_{lag} , intestinal absorption lag time; FaFg, intestinal availability; $f_{u,cim}$, unbound fraction in plasma; $K_{p,adipose}$, adipose/blood concentration ratio; $K_{p,muscle}$, muscle/blood centration ratio; $K_{p,skin}$, skin/blood concentration ratio; P_d , permeability value; λ , the ratio of passive diffusion for an ionized form to that for an unionized form; PS_{OCT2} , clearance by OCT2; $R_{OCT2,inf/eff}$, OCT2-mediated influx-to-efflux clearance ratio; PS_{OAT3} , clearance by OAT3; PS_{MATE} , clearance by MATEs; PS_{act} , hepatic active clearance; R_{dif} ,

passive-to-active clearance ratio; CL_{met}, hepatic metabolic clearance;

**: Value were calculated from Burt et al., 2016 including RAF.*

Reference for Supplemental Table 4

1. Burt, H.J. *et al.*, Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactions. *Eur. J. Pharm. Sci.* **88**, 70-82 (2016).
2. Umehara, K.I., Iwatubo, T., Noguchi, K., Kamimura, H. Functional involvement of organic cation transporter1 (OCT1/Oct1) in the hepatic uptake of organic cations in humans and rats. *Xenobiotica*. **37**, 818-831 (2007).
3. Balimane, P.V., Chong, S. Evaluation of permeability and P-glycoprotein interactions: industry outlook. In *Biopharmaceutics Applications in Drug Development*. (eds. Krishna, R., and Yu, L.) 101-138 (Springer, New York, 2008).
4. Yoshikado, T., *et al.*, Comparison of Methods for Estimating Unbound Intracellular-to-Medium Concentration Ratios in Rat and Human Hepatocytes Using Statins. *Drug. Metab. Dispos.* **45**, 779-789 (2017).
5. Chien, H.C. *et al.*, Rapid method to determine intracellular drug concentrations in cellular uptake assays: Application to metformin in organic cation transporter 1-transfected human embryonic kidney 293 cells. *Drug. Metab. Dispos.* **44**, 356-364 (2016).